glp-1/fgf21 agonist boehringer Frontiers Novel Therapies for Cardiometabolic Disease:

Short-acting GLP-1RAs keep working the same way on stomach emptying over time

when they reached their maximum dose), people taking Wegovy were eating 35% fewer calories than those on placebo and experienced nearly a 10% reduction in their body weight

Terns Pharmaceuticals announces positive phase 1 clinical trial results with TERN-601 once-daily oral GLP-1R agonist for the treatment of obesity(2024)

GLP-1s cost payers money upfront, but with member churn its unlikely a typical insurer will have the same enrollee ten years from now to realize potential cost-effectiveness or savings

Additionally, AMG133 explores a new strategy for treating obesity by targeting the GIP receptor and combining GLP-1 activity

This trial blows both of those results out of the water